Why the study?
Does a 6-month BPaLM regimen or 9-month all-oral regimen improve management of MDR/RR-TB compared to longer 18-month regimens?
Does a 6-month BPaLM regimen or 9-month all-oral regimen improve management of MDR/RR-TB compared to longer 18-month regimens?
The updated WHO guidelines recommend shorter, all-oral regimens (6-month BPaLM or 9-month) for MDR/RR-TB, replacing the traditional 18-month treatments.
No takes yet. Share an insight, caveat, or question.
Shorter regimens should now be first-line for MDR/RR-TB; extends trial evidence into updated WHO guidelines.
Vanino et al. (2023) conducted a review in Multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB). 6-month BPaLM regimen and 9-month all-oral regimen vs. Longer (18-month) regimens was evaluated. The updated WHO guidelines recommend a 6-month BPaLM regimen or a 9-month all-oral regimen over longer 18-month regimens for patients with multidrug-resistant/rifampicin-resistant tuberculosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: